HC Wainwright Has Positive Outlook for DTIL Q3 Earnings

Precision BioSciences, Inc. (NASDAQ:DTIL) – Investment analysts at HC Wainwright upped their Q3 2025 earnings estimates for shares of Precision BioSciences in a research note issued on Monday, August 11th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings of ($0.31) per share for the quarter, up from their prior estimate of ($0.38). HC Wainwright currently has a “Buy” rating and a $60.00 target price on the stock. The consensus estimate for Precision BioSciences’ current full-year earnings is ($1.23) per share. HC Wainwright also issued estimates for Precision BioSciences’ FY2025 earnings at ($4.57) EPS, Q1 2026 earnings at ($0.16) EPS, Q2 2026 earnings at ($0.16) EPS, Q3 2026 earnings at ($0.16) EPS, Q4 2026 earnings at $0.94 EPS, FY2026 earnings at $0.47 EPS, FY2027 earnings at $0.93 EPS, FY2028 earnings at $1.15 EPS and FY2029 earnings at $0.15 EPS.

Precision BioSciences Stock Performance

Precision BioSciences stock opened at $4.77 on Thursday. The company has a quick ratio of 5.18, a current ratio of 5.18 and a debt-to-equity ratio of 0.66. The company has a market capitalization of $56.24 million, a PE ratio of -0.54 and a beta of 1.52. The firm has a fifty day simple moving average of $4.69 and a two-hundred day simple moving average of $4.92. Precision BioSciences has a twelve month low of $3.61 and a twelve month high of $11.09.

Precision BioSciences (NASDAQ:DTIL) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($2.13) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($2.04). The business had revenue of $0.02 million during the quarter, compared to the consensus estimate of $6.27 million. Precision BioSciences had a negative return on equity of 176.47% and a negative net margin of 6,205.79%.

Institutional Trading of Precision BioSciences

Several hedge funds have recently added to or reduced their stakes in the business. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in Precision BioSciences by 22.0% in the fourth quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 15,534 shares of the company’s stock worth $59,000 after purchasing an additional 2,805 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Precision BioSciences by 5.5% during the second quarter. Geode Capital Management LLC now owns 77,712 shares of the company’s stock valued at $326,000 after acquiring an additional 4,025 shares during the last quarter. Miller Financial Services LLC bought a new position in shares of Precision BioSciences during the first quarter valued at about $48,000. XTX Topco Ltd bought a new position in shares of Precision BioSciences during the fourth quarter valued at about $67,000. Finally, Renaissance Technologies LLC raised its stake in shares of Precision BioSciences by 36.2% during the fourth quarter. Renaissance Technologies LLC now owns 109,798 shares of the company’s stock valued at $418,000 after acquiring an additional 29,200 shares during the last quarter. 37.99% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Precision BioSciences news, CFO John Alexander Kelly sold 14,827 shares of the business’s stock in a transaction on Thursday, July 3rd. The shares were sold at an average price of $4.26, for a total value of $63,163.02. Following the completion of the sale, the chief financial officer directly owned 73,485 shares of the company’s stock, valued at $313,046.10. The trade was a 16.79% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 4.50% of the stock is owned by corporate insiders.

Precision BioSciences Company Profile

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.